Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Sleep and circadian disorders in Alzheimer's disease (AD) are more frequent than in the general population and appear early in the course of the disease. Quality of sleep and quality of life are parallel in these patients, and such disorders also represent a heavy burden for caregivers. Although alterations in melatonin and hypocretins (orexins) seem to play a key role in the origin of these disturbances, the etiology of these disorders is multifactorial, including many factors such as environment, behavior, treatments, and comorbidities, among others. A comprehensive evaluation of sleep in each patient is essential in the design of the treatment that includes nonpharmacological and pharmacological approaches. One particularly interesting point is the possibility of a role of sleep disorders in the pathogenesis of AD, raising the possibility that treating the sleep disorder may alter the course of the disease. In this review, we present an update on the role of sleep disorders in AD, the bidirectional influence of sleep problems and AD, and treatment options. Behavioral measures, bright light therapy (BLT), melatonin, and other drugs are likely well known and correctly managed by the physicians in charge of these patients. In spite of the multiple treatments used, evidence of efficacy is scarce and more randomized double-blind placebo-controlled studies are needed. Future directions for treatment are the establishment of BLT protocols and the development of drugs with new mechanisms of action, especially hypocretin receptor antagonists, melatonin receptor agonists, and molecules that modulate the circadian clock.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity
de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X.-B., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L. F., Gautvik, V. T., Bartlett, F. S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.322 · Cited by 3,878 · cited 1×
“Hypocretin-1 and -2 are produced by a small cluster of neurons in the posterior hypothalamus.(51,52) The”
Neurons containing hypocretin (orexin) project to multiple neuronal systems
Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-09996.1998 · Cited by 3,466 · cited 1×
“Hypocretin-1 and -2 are produced by a small cluster of neurons in the posterior hypothalamus.(51,52) The”
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle
Kang, J.-E., Lim, M. M., Bateman, R. J., Lee, J. J., Smyth, L. P., Cirrito, J. R., Fujiki, N., Nishino, S., & Holtzman, D. M. (2009) · Science · doi:10.1126/science.1180962 · Cited by 1,565
Yaffe, K., Laffan, A. M., Harrison, S. L., Redline, S., Spira, A. P., Ensrud, K. E., Ancoli-Israel, S., & Stone, K. L. (2011) · JAMA · doi:10.1001/jama.2011.1115 · Cited by 1,137 · cited 2×
“35 However, Yaffe et al 36 found that the oxygen desaturation index and the percentage of time in apnea or hypopnea were associated with cognitive decline but not with sleep fragmentation or sleep duration.”
Sleep and Alzheimer disease pathology--a bidirectional relationship
Ju, Y.-E. S., Lucey, B. P., & Holtzman, D. M. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.269 · Cited by 996 · cited 1×
“Some authors have even suggested a possible preventive effect for the progression of the AD.(10,41,50,72) As mentioned in the previous section, a thorough evaluation, including habits, comorbidities, and treatments, is critical to choosing the most appropriate treatment for each patient.”
Riemersma-van der Lek, R. F. (2008) · JAMA · doi:10.1001/jama.299.22.2642 · Cited by 803 · cited 5×
“104 The season could have an effect on the response to BLT. Burns et al, 105 applying bright light at 1,000 lux from 10 am to 12 noon, found that the benefit was higher during winter than during summer.”
InfluentialLim, A. S. P., Kowgier, M., Yu, L., Buchman, A. S., & Bennett, D. A. (2013) · Sleep · doi:10.5665/sleep.2802 · Cited by 793 · cited 1×
“Some authors have even suggested a possible preventive effect for the progression of the AD.(10,41,50,72) As mentioned in the previous section, a thorough evaluation, including habits, comorbidities, and treatments, is critical to choosing the most appropriate treatment for each patient.”
Sleep Quality and Preclinical Alzheimer Disease
Ju, Y.-E. S., McLeland, J. S., Toedebusch, C. D., Xiong, C., Fagan, A. M., Duntley, S. P., Morris, J. C., & Holtzman, D. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.2334 · Cited by 744 · cited 1×
“45 The physiopathological mechanism is not completely understood, but an association between sleep disturbances and amyloid-β accumulation has been demonstrated in mice 10,11,40 and humans.”
Self-reported sleep and β-amyloid deposition in community-dwelling older adults
Spira, A. P., Gamaldo, A. A., An, Y., Wu, M. N., Simonsick, E. M., Bilgel, M., Zhou, Y., Wong, D. F., Ferrucci, L., & Resnick, S. M. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4258 · Cited by 570
Cited by
Sleep Disturbance, Cognitive Decline, and Dementia: A Review
Wu, M., Rosenberg, P., Spira, A., & Wennberg, A. (2017) · Seminars in Neurology · doi:10.1055/s-0037-1604351 · Cited by 309
Circadian disruption and sleep disorders in neurodegeneration
Shen, Y., Lv, Q.-K., Xie, W.-Y., Gong, S.-Y., Zhuang, S., Liu, J.-Y., Mao, C.-J., & Liu, C.-F. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00340-6 · Cited by 171
“There is evidence showing a reduction of melatonin level in the prodromal and progressive stages of AD [102].”
BackgroundThe discovery of suvorexant, the first orexin receptor drug for insomnia
Coleman, P. J., Gotter, A. L., Herring, W. J., Winrow, C. J., & Renger, J. J. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104837 · Cited by 128
Ahnaou, A., Moechars, D., Raeymaekers, L., Biermans, R., Manyakov, N. V., Bottelbergs, A., Wintmolders, C., Van Kolen, K., Van De Casteele, T., Kemp, J. A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13839-6 · Cited by 98
“hippocampus (HPC) CA1-CA3 networks; (2) phase-amplitude cross frequency coupling (PAC) between”
BackgroundA review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Metadata
- Authors
- Urrestarazu, E., & Iriarte, J.
- Venue
- Nature and Science of Sleep
- Publisher
- Informa UK Limited
- Published
- 2016-01
- Volume
- 8
- Pages
- 21
- ISSN
- 1179-1608 (ISSN-L)
- OpenAlex
- W2233936068
- Cited by
- 117
- References
- 37
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies. https://app.cochat.ai/papers/10.2147/nss.s76706
- The paper
- Urrestarazu, E., & Iriarte, J. (2016). Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies. Nature and Science of Sleep. https://doi.org/10.2147/nss.s76706
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.